olprinone and h 89

olprinone has been researched along with h 89 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J	1
Fujikawa, H; Kanno, T; Nagata, T; Nishizaki, T	1

Other Studies

2 other study(ies) available for olprinone and h 89

Article	Year
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation, 2001, Aug-07, Volume: 104, Issue:6 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Enzyme Inhibitors; Flavonoids; Hemodynamics; Imidazoles; Indoles; Isoquinolines; Maleimides; Milrinone; Mitogen-Activated Protein Kinases; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridines; Pyridones; Sulfonamides; Ventricular Fibrillation	2001
The phosphodiesterase III inhibitor olprinone inhibits hippocampal glutamate release via a cGMP/PKG pathway. Neuroscience letters, 2008, Dec-26, Volume: 448, Issue:2 Topics: Animals; Calcium; Carbazoles; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Excitatory Postsynaptic Potentials; Glutamic Acid; Hippocampus; Imidazoles; In Vitro Techniques; Isoquinolines; Male; Membrane Potentials; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Potassium; Protein Kinase Inhibitors; Pyramidal Cells; Pyridones; Rats; Rats, Wistar; Receptors, AMPA; Signal Transduction; Sulfonamides	2008

Article

Year

Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.

Circulation, 2001, Aug-07, Volume: 104, Issue:6

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Enzyme Inhibitors; Flavonoids; Hemodynamics; Imidazoles; Indoles; Isoquinolines; Maleimides; Milrinone; Mitogen-Activated Protein Kinases; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridines; Pyridones; Sulfonamides; Ventricular Fibrillation

2001

The phosphodiesterase III inhibitor olprinone inhibits hippocampal glutamate release via a cGMP/PKG pathway.

Neuroscience letters, 2008, Dec-26, Volume: 448, Issue:2

Topics: Animals; Calcium; Carbazoles; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Excitatory Postsynaptic Potentials; Glutamic Acid; Hippocampus; Imidazoles; In Vitro Techniques; Isoquinolines; Male; Membrane Potentials; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Potassium; Protein Kinase Inhibitors; Pyramidal Cells; Pyridones; Rats; Rats, Wistar; Receptors, AMPA; Signal Transduction; Sulfonamides

2008